3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
13
Squamous Cell Carcinoma of Head and Neck
11
Neoplasms
11
Prostatic Neoplasms
10
Breast Neoplasms
9
Recurrence
7
Ovarian Neoplasms
7
Myasthenia Gravis
7
Lung Neoplasms
7
Leukemia, Myeloid, Acute
7
Stomach Neoplasms
6
Head and Neck Neoplasms
6
Colorectal Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
5
Fatigue
5
Pancreatic Neoplasms
4
Oropharyngeal Neoplasms
4
Melanoma
4
Fallopian Tube Neoplasms
4
Colonic Neoplasms
4
Urinary Bladder Neoplasms
3
Rectal Neoplasms
3
Peritoneal Neoplasms
3
Mouth Neoplasms
3
Glioblastoma
3
Cholangiocarcinoma
3
Carcinoma, Hepatocellular
3
Anorexia
3
Adenocarcinoma Of Esophagus
3
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphatic Abnormalities
×
90 days
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled